Diagnosis and Treatment of Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysfunction in Patients with Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM)

References

• Wolfe F et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995 Jam38(1):19–28.
   Google Scholar
• Topbas M et al. The prevalence of fibromyalgia in women aged 20–64 in Tur-key. Scand J Rheumatol. 2005 Mar-Apr;34(2):140–4.
   Google Scholar
• Neumann L, Buskila D. Epidemiology of Fibromyalgia. Current Pain and Head-ache Reports 2003, 7:362–8.
   PubMedGoogle Scholar
• Wearden AJ, Morriss RK, Mullis R, et al. Randomized, double-blind, pla-cebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome [published erratum appears in Br J Psychiatry 1998;173:89]. Br J Psychiatry 1998. 172:485–90.
   PubMed Web of Science ®Google Scholar
• Vercoulen JH, Swanink CM, Zitman FG, et al. Randomized, double-blind, pla-cebo-controlled study of fluoxetine in chronic fatigue syndrome. The Lancet 1996; 347:858–61.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Rosen A, Pritchett YL, D' Souza DN, Goldstein DJ, Iyengar S, Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1-3):5–15.
   Google Scholar
• Barclay L, Vega C. Duloxetine Effective in Fibromyalgia. Medscape Medical News. Sept 10, 2004.
   Google Scholar
• Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Rus-sell IJ, Yunus MB. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum 1997 Sep;40(9):1571–9.
   Google Scholar
• Andersen MM, Permin H, Albrecht F. Illness and disability in Danish Chronic Fatigue Syndrome patients at diagnosis and 5-year follow-up. Journal of Psychoso-matic Research 2004;56: 217–29.
   Google Scholar
• Joyce J, Hotopf M, Wessely S. The prognosis of chronic fatigue syndrome: a systematic review. Q J Med 1997;90(3):223–33.
   Google Scholar
• Hoffman C, Rice D, Sung HY. Persons with chronic conditions. Their preva-lence and costs. JAMA. Vol. 276 No. 18, November 13, 1996.
   Google Scholar
• Levine PH et al. The Postinfectious Chronic Fatigue Syndrome. Humana Press, Clifton, NJ 1989:405–38.
   Google Scholar
• Deale A, Wessely S. Patients' perceptions of medical care in chronic fatigue syndrome. Social Science & Medicine 2001;52:1859–64.
   PubMed Web of Science ®Google Scholar
• Hinds GME, McCluskey DR. A retrospective study of chronic fatigue syn-drome. Proc Roy Coll Physicians, Edinburgh 1993; 23:10–14.
   Google Scholar
• Peterson PK, Schenck CH, Sherman R. Chronic fatigue syndrome in Minnesota. Minnesota Medicine 1991;74:21-6. Pain 1995;3: 91–110.
   Google Scholar
• Bennett RM: Fibromyalgia and the disability dilemma. A new era in under-standing a complex, multidimensional pain syndrome. Arthritis Rheum 1996;39: 1627–34.
   Google Scholar
• Kennedy M, Felson DT. A prospective long-term study of fibromyalgia syn-drome. Arthritis Rheum. 1996;39(4):682–5.
   PubMed Web of Science ®Google Scholar
• Wilson A et al. The treatment of chronic fatigue syndrome: science and specula-tion. Am J Med 1994;96(6):544–50.
   PubMed Web of Science ®Google Scholar
• Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJP et al. Evi-dence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73:1224–34.
   PubMed Web of Science ®Google Scholar
• Scott LV, Medbak S, Dinan TG. Blunted adrenocorticotropin and cortisol re-sponses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. Acta Psychiatr Scand 1998;97(6):450–7.
   Google Scholar
• Scott LV, Medbak S, Dinan TG. Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syn-drome and in healthy volunteers. Biol Psychiatry 1999;45 (11):1447–54.
   Google Scholar
• Cleare AJ, Miell J, Heap E, Sookdeo S, Young L, Malhi GS, O'Keane V. Hypothalamo-pituitary-adrenal axis function in chronic fatigue syndrome, and the ef-fects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab 2001;86:3545–54.
   Google Scholar
• Inder WJ� Prickett TC, Mulder RT. Normal opioid tone and hypothalamic-pitu-itary-adrenal axis function in chronic fatigue syndrome despite marked functional im-pairment. Clinical Endocrinology 2005;62:343–8.
   Google Scholar
• Gaab J, Huster D, Peisen R, Engert V, Heitz V, Schad T, Schurmeyer TH, Ehlert U. Hypothalamic-pituitary-adrenal axis reactivity in chronic fatigue syndrome and health under psychological, physiological, and pharmacological stimulation. Psychosom Med 2002;64(6):951–62.
   PubMed Web of Science ®Google Scholar
• Beam J, Allain T, Coskeran P, Munro N, Butler J, McGregor A, Wessely S Neuroendocrine responses to D-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. Biol Psychiatry 1995;37:245–52.
   PubMed Web of Science ®Google Scholar
• Dinan TG, Majeed T, Lavelle E, Scott LV, Berti C, Behan P. Blunted seroto-nin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinology 1997;22:261–7.
   PubMed Web of Science ®Google Scholar
• Riedel W, Layka H, Neeck. Secretory pattern of GH, TSH, thryoid hormones, ACTH, cortil, FSH, and LH in patients with fibromyalgia syndrome following sys-temic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 1998; 57:81–7.
   Google Scholar
• Griep EN, BoersmaJVV, de Kloet ER. Altered reactivity of the hypothalamic-pi-tuitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993;20: 469–74.
   Google Scholar
• Griep EN, BoersmaJW, Lentjes, Lentjes EG, Prins JK. Function of the hypotha-lamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol 1998;25(7):1374–81.
   Google Scholar
• Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RU. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum. 1994;37(11): 1583–92.
   PubMed Web of Science ®Google Scholar
• Calis M, Gokce C. Investigation of the hypothalamo-pituitary-adreanl axis (HPA) by lug ACTH test and metyrapone test in patients with primary fibromyalgia syndrome. J Endocrinol Invest 2004;27:42–6.
   PubMed Web of Science ®Google Scholar
• Torpy DJ et al. Responses of the sympathetic nervous system and the hypotha-lamic-pituitary-adrenal axis to interleukin-6 in fibromyalgia. Arthritis and Rheuma-tism. 2000;43:872–80.
   PubMed Web of Science ®Google Scholar
• Adler GK, Kinsley BT, Hurwitz S, Mossey C, Goldenberg DL. Reduced hypo-thalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 1999;106:534–43.
   Google Scholar
• Torpy DJ, Chrousos GP. The three-way interactions between the hypotha-lamic-pituitary-adrenal and gonadal axes and the immune system. B. Clinical Rheuma-tology 1996;10(2):181–98.
   PubMed Web of Science ®Google Scholar
• Scott LV, Medbak S, Dinan TG. The low dose ACTH test in chronic fatigue syndrome and in health. Clin Endocrinol (Oxf) 1998;48(6):733–7.
   PubMed Web of Science ®Google Scholar
• Soule S et al. The low dose ACTH stimulation test is less sensitive than the over-night metyrapone test for the diagnosis of secondary hypoadrenalism. Clinical Endo-crinology 2000;53:221.
   PubMed Web of Science ®Google Scholar
• Fiad TM, Kirby JM, Cunningham SK, McKenna TJ. The overnight single-dose metyrapone test is a simple and reliable index of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf) 1994;40(5):603–9.
   PubMed Web of Science ®Google Scholar
• Cunningham SK, Moore A, McKenna TJ. Normal cortisol response to corti-cotropin in patients with secondary adrenal failure. Arch Int Med 1983;143(12): 2276–9.
   Google Scholar
• Mayenknecht Jet al. Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. The Journal of Clinical Endocrinology & Me-tabolism 1998; 83(5):1558–62.
   PubMed Web of Science ®Google Scholar
• Kirnap M, Colak R, Eser C, Ozsoy O, Tutus A, Kelestimur F. A comparison be-tween low-dose (1 microg), standard-dose (250 microg) ACTH stimulation tests and insulin tolerance test in the evaluation of hypothalamo-pituitary-adrenal axis in pri-mary fibromyalgia syndrome. Clin Endocrinol (Oxf) 2001;55(4):455–9.
   Google Scholar
• Scott LV, Medbak S, Dinan TG. The low dose ACTH test in chronic fatigue syndrome and in health. Clin Endocrinol (Oxf) 1998;48:733–7.
   PubMed Web of Science ®Google Scholar
• Tordjman K, Jaffe A, Grazas N, Apter C, Stern N. The role of the low dose (1 microgram) adrenocorticotropin test in the evaluation of patients with pituitary dis-eases. Journal of Clinical Endocrinology & Metabolism 1995;80: 1301–5.
   Google Scholar
• Oelkers W. The role of high- and low-dose corticotropin tests diagnosis of sec-ondary adrenal insufficiency. European Journal of Endocrinology 1998;139:567–70.
   PubMed Web of Science ®Google Scholar
• Zarkovic M, Ciric J, Stojanovic M, et al. Optimizing the diagnostic criteria for standard (250-mg) and low dose (1-mg) adrenocorticotropin tests in the assessment of adrenal function. J Clin Endocrinol Metab 1999;84:3170–3.
   PubMed Web of Science ®Google Scholar
• Demitrack M, Dale J, Straus S, Laue L, Listwak S, Kruesi M, Chrousos G, Gold P. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in pa-tients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991;73:1224–34.
   PubMed Web of Science ®Google Scholar
• Scott LV, Dinan TG. Urinary free cortisol excretion in chronic fatigue syn-drome, major depression and in healthy volunteers. Journal of Affective Disorders 1998;47:49–54.
   PubMed Web of Science ®Google Scholar
• Cleare AJ, Blair D, Chambers S, Wessely S. Urinary free cortisol in chronic fa-tigue syndrome. Am J Psychiatry 2001;158:641–3.
   PubMed Web of Science ®Google Scholar
• Young et al. Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome. Boil Psychiatry 1998;43:236–7.
   PubMed Web of Science ®Google Scholar
• Maes M, Lin A, Bonaccorso S, Van Hunsel F, Van Gastel A, Delmeire L, Biondi M, Bosmans E, Kenis G, Scharpe S. Increased 24-hour urinary cortisol excre-tion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand 1998;98(4):328–35.
   Google Scholar
• De Becker P, De Meirleir K, Joos E, Campine I, Van Steenberge E, Smitz J, Velkeniers B. Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome. Horm Metab Res 1999;31(1):18–21.
   Google Scholar
• Crofford L. The hypothalamic-pituitary-adrenal stress axis in fibromyalgia and chronic fatigue syndrome. J Rheumatol 1998;57 Suppl 2:67–71.
   Google Scholar
• Kuratsune H, Yamaguti K, Sawada M, Kodate S, Machii T, Kanakura Y, Kitani T. Dehydroepiandrosterone sulfate deficiency in chronic fatigue syndrome. Int J Mol Med 1998;1(1):143–6.
   Google Scholar
• Strickland P, Morris R, Wearden A, Deakin B. A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls. J Affect Disord 1998;47(1-3):191–4.
   PubMed Web of Science ®Google Scholar
• Jefferies W. Mild adrenocortical deficiency, chronic allergies, autoimmune dis-orders and the chronic fatigue syndrome: a continuation of the cortisone story. Med Hypotheses 1994;3(42):183–9.
   Google Scholar
• Cleare AJ, Beam J, Allain T, McGregor A, Wessely S, Murray RM, O'Keane V. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord, 1995;18(4):283–9.
   Google Scholar
• Moutschen M, Triffaux TM, Demonty J, Legros JJ, Lefebvre PJ. Pathogenic tracks in fatigue syndromes. Acta Clin Be1g 1994;6(49): 274–89.
   Google Scholar
• Demitrack MA, Crofford U. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fa-tigue syndrome. Ann N Y Acad Sci 1998;840:684–97.
   PubMed Web of Science ®Google Scholar
• McLean SA et al. Momentary relationship between cortisol secretion and symp-toms in patients with fibromyalgia. Arthritis & Rheumatism 2005;52(11):3660–9.
   PubMed Web of Science ®Google Scholar
• Neeck G, Riedel. Thyroid Function in Patients with Fibromyalgia Syndrome. J Rheumatology 1992 ;19 (7): 1120–2.
   PubMed Web of Science ®Google Scholar
• Neeck G, Riedel W. Hormonal perturbations in fibromyalgia syndrome. Annals New York Academy of Sciences 1999;876:325–39.
   PubMed Web of Science ®Google Scholar
• Simons DG, Travell JG. Myofacial pain syndromes, perpetuation factors. In Textbook of Pain. P.D. Wall & R. Malzak, Eds.1989:369–85.
   Google Scholar
• McCain GA, Tilbe AK. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol 1989;16\(Supp19):154–7.
   Google Scholar
• Ferraccioli G, Cavalieri F, Salaffi F, Fontana S, Scita F, NoIli M, Maestri D. Neuroendocrinologic findings in primary fibromyalgia and in other rheumatic condi-tions. J. Rheumatol 1990;17:869–73.
   Google Scholar
• Englebienne P, Verhas M, Herst CV, Ke Meirleir K. Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasome: possible etiology for unexplained chronic fatigue. Med Hypoth 2003 ;60(2):175–80.
   Google Scholar
• Garrison RL, Breeding PC. A metabolic basis for fibromyalgia and its related disorders: the possible role of resistance to thyroid hormone. Medical Hypoth 2003; 61(2):182–9.
   PubMed Web of Science ®Google Scholar
• Cullum ME et al. Mutations in the c-erbAB1 gene: do they underlie euthyroid fibromyalgia. Medical Hypotheses 1997;48:125–35.
   PubMed Web of Science ®Google Scholar
• Lowe JC. Thyroid status of 38 Fibromyalgia Patients: Implications for the etiol-ogy of fibromyalgia. Clin Bulletin Myofascial Therapy 1997;2(1):47–64.
   Google Scholar
• Lowe JC, Reichman AJ, Honeyman GS, Yellin J. Thyroid status of fibro-myalgia patients. Clin Bulletin Myofascial Therapy 1998;3(1):69–70.
   Google Scholar
• Lowe JC. The Metabolic Treatment of Fibromyalgia. Ed., Yelin JC. McDowell Publishing Company 2000.
   Google Scholar
• Bennett RM, Clark SR, Campbell SM, Burckhardt CS. Low levels of somato-medin C in patients with fibromyalgia syndrome. A possible link between sleep and muscle pain. Arthritis and Rheumatism 1992;35(10):1110–13.
   Google Scholar
• Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM. Hypotha-lamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibro-myalgia. J Rheumatol. 1997; 24:1384–9.
   Google Scholar
• Bennett R. Growth hormone in musculoskeletal pain states. Current Pain and Headache Reports 2005;9:331–8.
   PubMedGoogle Scholar
• Bennett RM. Disordered growth hormone secretion in fibromyalgia: a review of recent findings and a hypothesized etiology. Z Rheumatol 1998;57\(Supp 2):72–6.
   Google Scholar
• Bennett RM, Clark SR, Walczyk J. A randomized, double-blind, placebo-con-trolled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998; 104:227–31.
   Google Scholar
• Behan WM. Muscles, mitochondria and myalgia. J Pathology 1992;166:213–14.
   PubMed Web of Science ®Google Scholar
• Riley MS, O'Brien CJ, McCluskey DR et al. Aerobic work capacity in patients with chronic fatigue syndrome. Brit Med J 1990;301:953–6.
   Google Scholar
• Behen WH, More IR, Behan PO. Mitochondria' abnormalities in postviral fa-tigue syndrome. Acta Neuropathol 1991;83:61–5.
   PubMedGoogle Scholar
• Nicolson G, Ellithorpe R. Lipid replacement and antioxidant nutritional therapy for restoring mitochondria' function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. Journal of Chronic Fatigue Syndrome 2006; 13(1):57–68.
   Google Scholar
• Pillemer S, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuro-science and endocrinology of FMS-[An NTH] conference summary. Arthritis & Rheu-matism 1997;40 (11):1928–39.
   PubMed Web of Science ®Google Scholar
• Drewes AM, Nielson KD, Taagholt SJ, Bjerregaard K, Svendson L, Gade J. Slow wave sleep in FMS. J Musculoskeletal Pain 1995;3(Suppl):29.
   Google Scholar
• Scharf MB, Baumann M, Berkowitz D. The effects of sodium oxybate on clini-cal symptoms and sleep patterns in patients with fibromyalgia. J Rheumatology 2003;30:1070–4.
   Google Scholar
• Moldofsky H. Sleep and musculoskeletal pain. Am J Med 1986;81:85–9.
   PubMed Web of Science ®Google Scholar
• Moldofsky H. Sleep and fibrositis syndrome. Rheum Dis Clin North Am 1989;15:91–103.
   PubMed Web of Science ®Google Scholar
• Moldofsky H. The contribution of sleep-wake physiology to fibromyalgia. Adv Pain Res Ther 1990;17:227–40.
   Google Scholar
• Klimas NG et al. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiology 1990;28(6): 1403–10.
   PubMed Web of Science ®Google Scholar
• Peterson A, Komaroff L, and Ritz J. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol 1987; 139:3306–13.
   Google Scholar
• Fletcher MA, Maher KJ, Klimas NG. Natural killer cell function in chronic fa-tigue syndrome 2002;2(2):129–39.
   Google Scholar
• Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis 1994;18\(Supp 1):S157–9.
   Google Scholar
• Komaroff A. The biology of chronic fatigue syndorme. Am J Med 2000; 108:169–71.
   PubMed Web of Science ®Google Scholar
• Vojdani et al. RNase L in health and disease: what did we learn recently? Jour-nal of Chronic Fatigue Syndrome 2003;11(2):97–109.
   Google Scholar
• Suhadolnik RJ et al. Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I) poly(C12U) in chronic fatigue syndrome. In Vivo. 1994;8:599–604.
   PubMedGoogle Scholar
• Suhadolnik RJ et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 1994;18:S96–S104.
   PubMed Web of Science ®Google Scholar
• Suhadolnik RJ et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon & Cytokine Res1997;17:377–85.
   PubMed Web of Science ®Google Scholar
• Suhadolnik RJ et al. Biochemical dysregulation of the 2-5A synthetase/RNase L antiviral defense pathway in chronic fatigue syndrome. J Chronic Fatigue Syndrome. 1999;5:223–42.
   Google Scholar
• De Meirleir K et al. A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome. Am J Med 2000;108(2):99–105.
   PubMed Web of Science ®Google Scholar
• Zorenzenon M, Rukh G Botta GA et al. Active HHV-6 infection in chronic fa-tigue syndrome patients from Italy: new data. J Chronic Fatigue Syndrome 1996; 2(4):3–12.
   Google Scholar
• Jo Nijs J et al. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients. FEMS Immunology & Medical Microbiology 2002;34: 209–14.
   Google Scholar
• Nicolson G, Nicolson N. Diagnosis and treatment of Mycoplasmal infections in Persian Gulf War Illness- CFIDSpatients. International Journal of Occupational Medi-cine, Immunology and Toxicology 1996;5:69–78.
   Web of Science ®Google Scholar
• Knox KK, Brewer JH, Carrigan DR. Persistent active human herpesvirus six (HHV-6) infections in patients with chronic fatigue syndrome. J Chronic Fatigue Syn-drome 1999;5: 245–6.
   Google Scholar
• Brewer JH, Know KK and Carrigan DR. Longitudinal study of chronic active human herpesvirus 6 (HHV-6) viremia in patients with chronic fatigue syndrome. Ab-stract. IDSA 37th Annual Meeting. Nov. 18–21, 1999. Philadelphia, Pennsylvania.
   Google Scholar
• Ablashi DV et al. Human herpes virus and chronic fatigue syndrome. Canad Dis Weekly Rep 1991;17S1:33–40.
   Google Scholar
• Josephs SF et al. HHV-6 reactivation in chronic fatigue syndrome. Lancet 1991;1346–7.
   PubMed Web of Science ®Google Scholar
• Nicolson GL, Gan R, Haier J. Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS 2003;111(5):557–66.
   Google Scholar
• Buchwald D. et al. A chronic illness characterized by fatigue, neurological and immunological disorders, and active human herpesvirus type 6 infection. Annals of In-ternal Medicine 1992;116:103–13.
   PubMed Web of Science ®Google Scholar
• Martin WJ. Detection of viral related sequences in CFS patients using the poly-merase chain reaction. In "The Clinical and Scientific Basis of Myalgic Encephalo-myelitis Chronic Fatigue Syndrome." Byron M. Hyde Editor. Nightingale Research Foundation Press. Ottawa, Canada, pp. 278–83, 1992.
   Google Scholar
• Rowe PC, Bou-Holaigah I, Kan JS, Calkins H. Is NMH an unrecognized cause of chronic fatigue? Lancet 1995;345:623–4.
   PubMed Web of Science ®Google Scholar
• Naschitz JE, Rosner I, Rozenboum Metal. The head-up tilt test with haemo dy-namic instability score in diagnosing chronic fatigue syndrome. QJ Med 2003;96: 133–42.
   Google Scholar
• Gerrity TR, Bates J, Bell DS, Chrousos G, Furst G, Hedrick T, Hurwitz B, Kula RW, Levine SM, Moore RC, Schondorf R. Chronic fatigue syndrome: what role does the autonomic nervous system play in the pathophysiology of this complex illness? NeuroImmunoModulation 2002;10:134–41.
   Google Scholar
• Wallace DJ, Gallegua DS. Fibromyalgia: the gastrointestinal link. Current Pain and Headache Reports 2004;8:364–8.
   PubMedGoogle Scholar
• Sivri A, Cindas A, Dincer F, Sivri B. Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients. Clin Rheumatol 1996;15(3):283–6.
   PubMed Web of Science ®Google Scholar
• Triadafilopoulos G, Simms RW, Goldenberg DL. Bowel dysfunction in fibro-myalgia syndrome. Dig Dis Sci 1991;36(1):59–64.
   Google Scholar
• Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, Lin HC. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Annals of the Rheumatic Diseases 2004;63:450–2.
   Google Scholar
• Mark Pimentel et al. Small intestinal bacterial overgrowth: a possible associa-tion with fibromyalgia. Journal of Musculoskeletal Pain 2001;9(3):107–13.
   Web of Science ®Google Scholar
• Berg D, Berg LH, Couvaras J, Harrison H. Chronic Fatigue Syndrome (CFS) &/or Fibromyalgia (FM) as a Variation of Antiphospholipid Antibody Syndrome (APS): An Explanatory Model and Approach to Laboratory Diagnosis of Blood Coag-ulation and Fibrinolysis 1999;10:1–4.
   Google Scholar
• Berg D, Berg LH, Couvaras J. Is CFS/FM due to an undefined hypercoaguable state brought on by immune activation of coagulation. Does adding anticoagulant ther-apy improve CFS/FM patient symptoms? AACFS Proceedings, Cambridge, MA, 10 –12 October 1998:62.
   Google Scholar
• Berg D, Berg LH, Harrison H, Dreschsel. Retrospective study of 400+ CFS/FM patients for immune system activation of coagulation and hereditary coagulation de-fects as predisposition for CFS/FM. Proceedings International Society Thrombosis & Hemostasis July, 2001.
   Google Scholar
• Harrison H, Ryser CA� Brewer J, Berg D. Procoagulant Genetic Factors in a Pooled Cohort of 582 Chronic Fatigue Syndrome, Fibromyalgia and Related Chronic Illness Cases. VIIth International Conference American Association for Chronic Fa-tigue Syndrome (AACFS), Oct, 2004, Madison, WI, USA
   Google Scholar
• Berg D, Berg LH, Harrison H. Low Level Activation of Coagulation with Coagulopathies in the Etiology of CFS / FM and Chronic Illnesses. An Explanatory Model Revisited. VIIth International Conference, American Association for Chronic Fatigue Syndrome (AACFS) Meeting, Madison, WI, Oct, 2004.
   Google Scholar
• Harrison HH, Ryser CA, Ryser ME, et al. Use of sensitive markers of coagula-tion activation to monitor low dose heparin therapy in patients with CFS and FM. Clin-ical Chemistry 2003 ;49(56):A9.
   Google Scholar
• Teitelbaum J, Bird B, Greenfield R, Weiss A, Muenz L, Gould L. Effective treatment of chronic fatigue syndrome (CFIDS) & fibromyalgia (FMS)�A randomized, double-blind, placebo-controlled, intent to treat study. Journal of Chronic Fatigue Syn-drome 2001;8(2):3–28.
   Google Scholar
• Blatman H. Effective Treatment of fibromyalgia and myofascial pain syn-drome: a clinician's perspective. American Journal of Pain Management (Journal of the American Academy of Pain Management) 2002;12(2):67–8.
   Google Scholar
• American Academy of Environmental Medicine 38th Annual Meeting, Identi-fying the Cause and Exploring the Newest Treatment Option for Chronic Fatigue Syn-drome, Fibromyalgia and Environmental Sensitivities, Phoenix, AZ, Oct 30-Nov 2, 2003.
   Google Scholar
• De Meirleir K, Englebienne P. Chronic Fatigue Syndrome: A Biological Ap-proach. CRC Press. 2002.
   Google Scholar
• Teitelbaum J. Effective treatment of chronic fatigue syndrome: clinical proto-cols and practice. Integrative Medicine 2005;4(4):CD-CG.
   Google Scholar
• International Association for Chronic Fatigue Syndrome (IACFS), Centers for Disease Control and Prevention (CDC) and the National Center for Infectious Dis-eases. Seventh International Conference on Chronic Fatigue Syndrome, Fibromyalgia and Other Related Illnesses. October 8–10, Madison, Wisconsin 2004.
   Google Scholar
• International Association for Chronic Fatigue Syndrome (IACFS), Centers for Disease Control and Prevention (CDC) and PANDORA. Eighth International Confer-ence on Chronic Fatigue Syndrome, Fibromyalgia and Other Related Illnesses. Fort Lauderdale, FL, Jan 12–14, 2007.
   Google Scholar
• Effective Treatment of Chronic Fatigue Syndrome, Pain and Fibromyalgia�A Double-blind Study. The 12th Annual World Congress on Anti-Aging Medicine, Las Vegas, NV 2005.
   Google Scholar
• Latest 21st Century Advances in the Diagnosis & Treatment of Fibromyalgia, Chronic Fatigue Syndrome and Related Illnesses. Los Angeles, CA, Sept 19–21, 2002.
   Google Scholar
• Ali M et al. Efficacy of ecologic-integrative management; protocols for rever-sal of fibromyalgia. J Integrative Medicine 1999;3:48–64.
   Google Scholar
• Lowe JC, Reichman AJ, Yellin J. The process of change during T3 treatment for euthyroid fibromyalgia: a double-blind placebo-controlled crossover study. Clini-cal Bulletin of Myofascial Therapy 1997;2(2/3):91–124.
   Google Scholar
• PreAmerican Association for CFS/FMS 7th International Conference. A clini-cally focused workshop on Effective CFS/Fibromyalgia Therapies. October 7, 2004 Madison, Wisconsin.
   Google Scholar
• Potential Unique etiologies of Chronic Fatigue Syndrome and Fibromyalgia: Hypercoaguable State, Neurotoxins & Heavy Metals. Fifth Annual Fibromyalgia and Chronic Fatigue Conference. Kansas City, MO. Fibromyalgia Coalition International May 14, 2005.
   Google Scholar
• Hormone Replacement Therapy in the Treatment of Fibromyalgia and CFIDS/ Fibromyalgia CME Conference National Fibromyalgia Association. Garden Grove, CA. May 18, 2006.
   Google Scholar
• The Treatment of the Metabolic Consequences of CFS/FM and Chronic Infec-tions. American College for the Advancement of Medicine. Dallas, TX. May 4, 2006.
   Google Scholar